Kinnate Biopharma Inc. (KNTE) NASDAQ

$2.66 - (-)

Market Cap: $125.32M

As of 03/28/24 04:00 PM EDT. Market closed.

Kinnate Biopharma Inc. (KNTE)
NASDAQ

$2.66
- (-)

Market Cap: $125.32M

As of 03/28/24 04:00 PM EDT. Market closed.

Add to Portfolio

kinnate biopharma inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors for treating genomically defined cancers. the company's lead product candidate is kin002787, which is a rapidly accelerated fibrosarcoma inhibitor that is in preclinical stage for the treatment of patients with lung cancer, melanoma, and other solid tumors. its other ... read more

kinnate biopharma inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors for treating genomically defined cancers. the company's lead product candidate is kin002787, which is a rapidly accelerated fibrosarcoma inhibitor that is in preclinical stage for the treatment of patients with lung cancer, melanoma, and other solid tumors. its other products in preclinical stage include kin003, which are small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors (fgfr)2 and fgfr3 genes; and small molecule research programs, including a cyclin-dependent kinase 12 inhibitor in its kin004 program. kinnate biopharma inc. was founded in 2018 and is headquartered in san diego, california. read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
URL
Address
103 Montgomery Street, Suite 150, CA, San Francisco, 94129.
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Nima Farzan
Address
103 Montgomery Street, Suite 150, CA, San Francisco, 94129.
PRICE CHART FOR KINNATE BIOPHARMA INC
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$2.66
Previous Close
$2.66
Days Range
$2.64 - $2.67
52 week range
$1.04 - $7.19
Volume
518,478
Avg. Volume (30 days)
475,917
Market Cap
$125.32M
Dividend Yield
-
P/E
-
Shares Outstanding
47,112,698
Open
$2.66
Previous Close
$2.66
Days Range
$2.64 - $2.67
52 week range
$1.04 - $7.19
Volume
518,478
Avg. Volume (30 days)
475,917
Market Cap
$125.32M
Dividend Yield
-
P/E
-
Shares Outstanding
47,112,698
FINANCIAL STATEMENTS FOR KINNATE BIOPHARMA INC
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR KINNATE BIOPHARMA INC
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
Williams Richard ThomasChief Medical OfficerDec 01, 2023 Option Exercise$2.255411,21768,146Dec 05, 2023, 05:00 PM
Krishnamohan NehaChief Financial OfficerDec 01, 2023 Option Exercise$2.251,4593,28365,593Dec 05, 2023, 05:00 PM
Meltz Mark ACOO General Counsel SecretaryDec 01, 2023 Option Exercise$2.255411,21728,136Dec 05, 2023, 05:00 PM
Krishnamohan NehaChief Financial OfficerSep 01, 2023 Option Exercise$2.351,4593,42967,052Sep 06, 2023, 05:00 PM
Meltz Mark ACOO General Counsel SecretarySep 01, 2023 Option Exercise$2.355411,27128,677Sep 06, 2023, 05:00 PM
Williams Richard ThomasChief Medical OfficerSep 01, 2023 Option Exercise$2.355411,27168,687Sep 06, 2023, 05:00 PM
Williams Richard ThomasChief Medical OfficerJun 01, 2023 Option Exercise$4.305412,32669,228Jun 05, 2023, 05:01 PM
Meltz Mark ACOO General Counsel SecretaryJun 01, 2023 Option Exercise$4.305412,32629,218Jun 05, 2023, 05:00 PM
Krishnamohan NehaChief Financial OfficerJun 01, 2023 Option Exercise$4.301,4596,27468,511Jun 05, 2023, 05:00 PM
Tananbaum James B.DirectorMay 08, 2023 Buy$2.801,780,0004,984,0003,525,957May 10, 2023, 05:49 PM
Foresite Capital Management IV, LLC10% OwnerMay 08, 2023 Buy$2.801,780,0004,984,0003,525,957May 10, 2023, 05:42 PM
ORBIMED ADVISORS LLCDirectorMay 04, 2023 Buy$2.75479,9091,319,7504,738,453May 08, 2023, 05:22 PM
ORBIMED ADVISORS LLCDirectorMay 05, 2023 Buy$2.82981,0232,766,4851,368,339May 08, 2023, 05:22 PM
GORDON CARL LDirectorMay 05, 2023 Buy$2.82981,0232,766,4851,368,339May 08, 2023, 05:11 PM
GORDON CARL LDirectorMay 04, 2023 Buy$2.75479,9091,319,7504,738,453May 08, 2023, 05:11 PM
GORDON CARL LDirectorMay 02, 2023 Buy$2.67338,262903,1604,425,462May 02, 2023, 09:38 PM
GORDON CARL LDirectorMay 01, 2023 Buy$2.62716,1571,876,3314,204,852May 02, 2023, 09:38 PM
GORDON CARL LDirectorApr 28, 2023 Buy$2.55350,749894,4103,737,784May 02, 2023, 09:38 PM
ORBIMED ADVISORS LLCDirectorMay 02, 2023 Buy$2.67338,262903,1604,425,462May 02, 2023, 09:34 PM
ORBIMED ADVISORS LLCDirectorMay 01, 2023 Buy$2.62716,1571,876,3314,204,852May 02, 2023, 09:34 PM
ORBIMED ADVISORS LLCDirectorApr 28, 2023 Buy$2.55350,749894,4103,737,784May 02, 2023, 09:34 PM
Williams Richard ThomasChief Medical OfficerMar 01, 2023 Option Exercise$5.216383,32467,295Mar 03, 2023, 05:58 PM
Meltz Mark ACOO General Counsel SecretaryMar 01, 2023 Option Exercise$5.216383,32427,286Mar 03, 2023, 05:57 PM
Krishnamohan NehaChief Financial OfficerMar 01, 2023 Option Exercise$5.211,7218,96667,378Mar 03, 2023, 05:56 PM
Williams Richard ThomasChief Medical OfficerDec 01, 2022 Option Exercise$7.755414,19367,933Dec 02, 2022, 08:00 PM
Krishnamohan NehaChief Financial OfficerDec 01, 2022 Option Exercise$7.751,45911,30769,099Dec 02, 2022, 08:00 PM
Meltz Mark ACOO General Counsel SecretaryDec 01, 2022 Option Exercise$7.755414,19327,924Dec 02, 2022, 08:00 PM
Williams Richard ThomasChief Medical OfficerMar 14, 2022 Buy$8.3725,000209,25042,333Mar 15, 2022, 05:01 PM
Williams Richard ThomasChief Medical OfficerMar 11, 2022 Buy$8.6415,000129,60017,333Mar 15, 2022, 05:01 PM
GORDON CARL LDirectorFeb 11, 2022 Buy$10.22156,0001,594,3203,469,330Feb 15, 2022, 09:51 PM
GORDON CARL LDirectorFeb 15, 2022 Buy$9.969,00089,6403,509,030Feb 15, 2022, 09:51 PM
GORDON CARL LDirectorFeb 14, 2022 Buy$9.9530,700305,4863,500,030Feb 15, 2022, 09:51 PM
ORBIMED ADVISORS LLCDirectorFeb 15, 2022 Buy$9.969,00089,6403,509,030Feb 15, 2022, 09:42 PM
ORBIMED ADVISORS LLCDirectorFeb 14, 2022 Buy$9.9530,700305,4863,500,030Feb 15, 2022, 09:42 PM
ORBIMED ADVISORS LLCDirectorFeb 11, 2022 Buy$10.22156,0001,594,3203,469,330Feb 15, 2022, 09:42 PM
Tananbaum James B.DirectorDec 03, 2020 Buy$20.001,000,00020,000,000500,000Dec 04, 2020, 09:39 PM
Foresite Capital Management IV, LLC10% OwnerDec 03, 2020 Option Exercise$20.001,000,00020,000,000500,000Dec 04, 2020, 08:57 PM
ORBIMED ADVISORS LLCDirectorDec 02, 2020 Buy$20.00750,00015,000,000450,000Dec 04, 2020, 06:11 PM
GORDON CARL LDirectorDec 02, 2020 Buy$20.00750,00015,000,000450,000Dec 04, 2020, 05:13 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
Williams Richard ThomasChief Medical Officer12/01/20231,217
Krishnamohan NehaChief Financial Officer12/01/20233,283
Meltz Mark ACOO General Counsel Secretary12/01/20231,217
Krishnamohan NehaChief Financial Officer09/01/20233,429
Meltz Mark ACOO General Counsel Secretary09/01/20231,271
Williams Richard ThomasChief Medical Officer09/01/20231,271
Williams Richard ThomasChief Medical Officer06/01/20232,326
Meltz Mark ACOO General Counsel Secretary06/01/20232,326
Krishnamohan NehaChief Financial Officer06/01/20236,274
Tananbaum James B.Director05/08/20234,984,000
Foresite Capital Management IV, LLC10% Owner05/08/20234,984,000
ORBIMED ADVISORS LLCDirector05/04/20231,319,750
ORBIMED ADVISORS LLCDirector05/05/20232,766,485
GORDON CARL LDirector05/05/20232,766,485
GORDON CARL LDirector05/04/20231,319,750
GORDON CARL LDirector05/02/2023903,160
GORDON CARL LDirector05/01/20231,876,331
GORDON CARL LDirector04/28/2023894,410
ORBIMED ADVISORS LLCDirector05/02/2023903,160
ORBIMED ADVISORS LLCDirector05/01/20231,876,331
ORBIMED ADVISORS LLCDirector04/28/2023894,410
Williams Richard ThomasChief Medical Officer03/01/20233,324
Meltz Mark ACOO General Counsel Secretary03/01/20233,324
Krishnamohan NehaChief Financial Officer03/01/20238,966
Williams Richard ThomasChief Medical Officer12/01/20224,193
Krishnamohan NehaChief Financial Officer12/01/202211,307
Meltz Mark ACOO General Counsel Secretary12/01/20224,193
Williams Richard ThomasChief Medical Officer03/14/2022209,250
Williams Richard ThomasChief Medical Officer03/11/2022129,600
GORDON CARL LDirector02/11/20221,594,320
GORDON CARL LDirector02/15/202289,640
GORDON CARL LDirector02/14/2022305,486
ORBIMED ADVISORS LLCDirector02/15/202289,640
ORBIMED ADVISORS LLCDirector02/14/2022305,486
ORBIMED ADVISORS LLCDirector02/11/20221,594,320
Tananbaum James B.Director12/03/202020,000,000
Foresite Capital Management IV, LLC10% Owner12/03/202020,000,000
ORBIMED ADVISORS LLCDirector12/02/202015,000,000
GORDON CARL LDirector12/02/202015,000,000
Load More Insider Transactions
FUNDS WITH A POSITION IN KINNATE BIOPHARMA INC
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
ORBIMED ADVISORS LLC7,559,7290.39%-5.62%Other
VIKING GLOBAL INVESTORS LP1,820,4620.02%No changeGrowth At A Reasonable Price
BLACKROCK INC.586,6880.00004%-20.86%Other
RENAISSANCE TECHNOLOGIES LLC574,9790.00211%13.64%Other
GEODE CAPITAL MANAGEMENT, LLC230,7530.00006%4.17%Other
D. E. SHAW & CO., INC.150,6950.00031%170.01%Other
CHANGE IN SHARES OUTSTANDING FOR KINNATE BIOPHARMA INC
STOCK BUYBACKS FOR KINNATE BIOPHARMA INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
09/30/2023
06/30/2023
0.94%
1Q
09/30/2023
03/31/2023
3.71%
2Q
09/30/2023
12/31/2022
6.49%
3Q
09/30/2023
09/30/2022
6.67%
4Q
09/30/2023
06/30/2022
7.03%
5Q
09/30/2023
03/31/2022
7.32%
6Q
09/30/2023
12/31/2021
7.71%
7Q
09/30/2023
09/30/2021
7.86%
8Q
09/30/2023
06/30/2021
8.17%
9Q
09/30/2023
03/31/2021
8.32%
10Q
Load More

Period of Report: 09/30/2023

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
06/30/2023
0.94%
1Q
03/31/2023
3.71%
2Q
12/31/2022
6.49%
3Q
09/30/2022
6.67%
4Q
06/30/2022
7.03%
5Q
03/31/2022
7.32%
6Q
12/31/2021
7.71%
7Q
09/30/2021
7.86%
8Q
06/30/2021
8.17%
9Q
03/31/2021
8.32%
10Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR KINNATE BIOPHARMA INC
LOADING...